382 related articles for article (PubMed ID: 35341809)
21. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
[TBL] [Abstract][Full Text] [Related]
22. Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.
Schulz SR; Hoffmann M; Roth E; Pracht K; Burnett DL; Mazigi O; Schuh W; Manger B; Mielenz D; Goodnow CC; Christ D; Pöhlmann S; Jäck HM
Eur J Immunol; 2022 Jun; 52(6):970-977. PubMed ID: 35253229
[TBL] [Abstract][Full Text] [Related]
23. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
24. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
25. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants.
Coutant F; Touret F; Pin JJ; Alonzo M; Baronti C; Munier S; Attia M; de Lamballerie X; Ferry T; Miossec P
Emerg Microbes Infect; 2024 Dec; 13(1):2307510. PubMed ID: 38240255
[TBL] [Abstract][Full Text] [Related]
27. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
[TBL] [Abstract][Full Text] [Related]
28. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
[TBL] [Abstract][Full Text] [Related]
29. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
[TBL] [Abstract][Full Text] [Related]
30. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
[TBL] [Abstract][Full Text] [Related]
33. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
[TBL] [Abstract][Full Text] [Related]
34. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; Zhang B; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
Cell Rep; 2022 Nov; 41(5):111528. PubMed ID: 36302375
[TBL] [Abstract][Full Text] [Related]
35. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
[TBL] [Abstract][Full Text] [Related]
37. Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.
Furuse Y
J Med Virol; 2023 Jan; 95(1):e28275. PubMed ID: 36326059
[TBL] [Abstract][Full Text] [Related]
38. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
[TBL] [Abstract][Full Text] [Related]
39. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.
Touret F; Baronti C; Bouzidi HS; de Lamballerie X
Sci Rep; 2022 Mar; 12(1):4683. PubMed ID: 35304531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
